For the novel coronavirus pneumonia, which is not available for effective treatment, the Regeneron Pharmaceuticals developed the antibody cocktail treatment method authorized by the US Food and Drug Administration (FDA). On November 21st, novel coronavirus pneumonia was being studied in the US, and the antibody cocktail of CACI monoclonal antibody and REGN-COV2 was used (REGEN-COV2 or also). The treatment has been urgently authorized by the food and drug administration.
The novel coronavirus pneumonia, novel coronavirus pneumonia, and 2 children with at least 12 kg and at least 40 kg were treated with these two McAbs. The patients were also tested for the new virus and had a high risk of developing severe new crown pneumonia or hospitalization. Clinical evidence from Regent's out-patient trials has shown that patients given early after diagnosis without producing an autoimmune response or high viral load, such as regen-cov2 monoclonal antibodies, have the greatest benefit.
President trump used the company's "antibody cocktail therapy" after being infected with the new coronavirus. After leaving hospital, trump also praised the treatment, promising to approve its emergency use and provide it free of charge to all Americans.
Trump also said in an interview with the media that the therapy is a "game changer" and "better than a vaccine".
Antibody cocktail therapy is designed to neutralize the virus by using very effective antibodies to mimic the effects of a functioning immune system. Data from about 800 non-hospitalized patients showed a significant decrease in virus levels within days of receiving antibody cocktail therapy, which was associated with a significant decrease in visits. This benefit is greatest in patients who are most likely to have poor prognosis due to high viral load, and immune responses are ineffective at baseline or prior risk factors. To date, clinical trial analysis has found no variants resistant to cocktails, consistent with our preclinical findings ." Dr. George D· Young Copros, president and chief scientific officer of Regenerative Yuan, said.
The production of monoclonal antibody is a complex, time-consuming and laborious process, which requires deep professional knowledge. By the end of November, the company expects to prepare antibody cocktail treatment doses for about 80000 patients, about 200000 patients by the first week of January 2021, and a total of 300000 patients by the end of January 2021.
"The antibody cocktail therapy, based on the velocimmune platform of the company, is composed of two highly active neutralizing antibodies against sars-cov-2 (regn10933 and regn10987). It became famous because it was given to the president of the United States who diagnosed covid-19 in early October. However, follow-up studies found that it could not effectively improve the condition of critically hospitalized covid-19 patients." American immunology Doctor Wang Yuge thinks.
So far, more than 7000 people have participated in clinical trials of antibody cocktail therapy.
According to real-time statistics released by Johns Hopkins University, as of November 22,2020, at 08:40, Beijing time ,58014491 new crown patients ,1378866 deaths and 191 countries and regions were diagnosed globally.